Combination CDC-like kinase inhibition (CLK)/Dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy in CTNNB1-mutated endometrial cancer

SM08502 (cirtuvivint) is a novel pan CDC-like kinase (CLK) and Dual specificity tyrosine kinase (DYRK) inhibitor that targets mRNA splicing and is optimized for Wnt pathway inhibition. Previous evaluation of single agent CLK/DYRK inhibition (SM04690) demonstrated inhibition of tumor progression and...

Descripción completa

Detalles Bibliográficos
Autores principales: Corr, Bradley R, Moroney, Marisa R, Woodruff, Elizabeth, Watson, Zachary L, Jordan, Kimberly R., Danhorn, Thomas, Bailey, Courtney, Wolsky, Rebecca J, Bitler, Benjamin G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10104048/
https://www.ncbi.nlm.nih.gov/pubmed/37066339
http://dx.doi.org/10.1101/2023.04.04.535570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10104048/
https://www.ncbi.nlm.nih.gov/pubmed/37066339
http://dx.doi.org/10.1101/2023.04.04.535570

Ejemplares similares